Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. SPY
2. NVDA
3. AVAV
4. NKE
5. MU
6. DLR
7. EOSE
8. TSLA
9. VSH
10. AAPL

Go back to Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences (NERV) to Resume Trading at 9:50 am

May 29, 2020 9:26 AM EDT

Minerva Neurosciences (NASDAQ: NERV) to Resume Trading at 9:50 am

... More